Last 46 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.06 | — | — | — | — | 1.43 | — | 3.67 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.28 | 0.58 | 0.43 | 0.66 | 0.24 | 0.13 | 0.22 | 0.32 | 0.22 | 0.30 | 0.21 | 0.21 | 0.05 | 0.09 | 0.11 | 0.09 | 0.23 | 0.33 | 0.39 | 0.87 | 1.26 |
| — | +333.3% | +93.5% | +104.3% | +8.7% | -55.5% | +6.4% | +55.4% | +325.6% | +226.1% | +85.9% | +139.8% | -76.6% | -72.2% | -70.8% | -90.0% | -82.0% | -87.0% | -70.4% | -67.7% | -58.2% | |
| P/B Ratio | 0.75 | 0.82 | 1.84 | 1.58 | 0.78 | 0.28 | 0.47 | 0.72 | 0.58 | 0.55 | 0.48 | 0.46 | 0.17 | 0.20 | 0.26 | 0.18 | 0.56 | 0.52 | 0.34 | 0.68 | 0.86 |
| — | +189.4% | +291.9% | +120.4% | +33.8% | -48.4% | -1.7% | +55.9% | +253.5% | +167.5% | +84.9% | +158.9% | -70.6% | -60.9% | -23.6% | -73.9% | -34.8% | -45.3% | -51.8% | -57.2% | -54.4% | |
| P/FCF | — | — | 1.78 | — | 1.33 | — | 1.24 | — | — | — | — | — | 0.17 | — | — | — | — | — | — | — | — |
| — | — | +43.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 0.95 | — | 9.79 | — | — | 0.73 | 2.84 | 1.52 | — | — | 5.76 | — | — | — | — | — |
| — | — | — | — | — | — | — | +245.1% | — | — | — | -50.7% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 3.14 | — | 0.75 | 1.91 | 1.95 | — | — | 1.35 | — | 1.24 | — | — | — | — | — | — | — | — |
| — | — | — | +60.8% | — | — | +41.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0% | 55.1% | 60.0% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 66.2% | 73.9% | 77.9% | 73.2% | 60.4% | 56.1% | 65.8% | 65.2% | 46.8% | 52.4% | 53.2% | 56.9% | 48.1% |
| — | -20.6% | -9.8% | -8.5% | +2.3% | -6.1% | -14.6% | -1.2% | +9.6% | +31.8% | +18.4% | +12.2% | +29.1% | +6.9% | +23.7% | +14.6% | -2.8% | +1663.8% | -9.4% | -18.7% | -25.2% | |
| Operating Margin | -11.8% | -32.7% | -13.0% | -10.8% | -50.4% | 13.1% | -10.4% | -5.6% | -20.3% | -11.4% | 16.8% | -4.9% | 0.5% | -37.6% | -26.1% | -6.5% | -61.7% | -220.8% | -48.8% | -126.5% | -102.5% |
| — | -349.6% | -24.3% | -93.0% | -148.1% | +215.2% | -162.3% | -15.3% | -3792.5% | +69.8% | +164.2% | +25.6% | +100.9% | +82.9% | +46.5% | +94.8% | +39.8% | -16.0% | -32.7% | -380.8% | -129.6% | |
| Net Margin | -20.4% | -45.3% | -69.8% | 14.1% | -130.9% | 21.6% | 4.9% | 8.9% | -25.7% | -20.6% | -1.2% | -45.6% | -8.0% | -31.7% | -25.5% | -2.5% | -58.6% | -220.2% | -49.9% | -127.2% | -80.9% |
| — | -309.1% | -1536.7% | +59.1% | -409.8% | +205.2% | +514.0% | +119.5% | -221.3% | +35.0% | +95.4% | -1698.0% | +86.4% | +85.6% | +49.0% | +98.0% | +27.5% | -16.6% | +20.6% | -299.4% | -282.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -22.8% | -56.6% | 9.3% | -73.6% | 12.2% | 2.6% | 5.1% | -15.8% | -9.1% | -0.7% | -22.7% | -6.1% | -16.6% | -13.4% | -1.4% | -30.5% | -63.9% | -10.6% | -22.4% | -13.5% |
| — | -287.2% | -2277.7% | +82.0% | -366.1% | +234.1% | +484.4% | +122.6% | -157.9% | +45.3% | +95.0% | -1490.6% | +79.9% | +74.0% | -26.1% | +93.6% | -125.4% | -221.3% | -13.8% | -383.2% | -288.8% | |
| ROA | -11.2% | -4.8% | -8.6% | 1.6% | -16.0% | 3.3% | 0.7% | 1.3% | -3.7% | -2.2% | -0.2% | -6.0% | -1.7% | -5.0% | -4.6% | -0.5% | -10.5% | -27.1% | -5.1% | -11.3% | -7.1% |
| — | -244.7% | -1362.0% | +25.6% | -328.1% | +249.7% | +507.6% | +120.9% | -116.2% | +55.5% | +96.4% | -1130.7% | +83.6% | +81.6% | +10.2% | +95.7% | -48.5% | -133.6% | +17.3% | -286.2% | -251.0% | |
| ROIC | -33.5% | -15.8% | -11.8% | -7.9% | -22.8% | 5.4% | -4.6% | -2.7% | -9.5% | -3.7% | 7.9% | -1.7% | 0.3% | -13.1% | -9.6% | -2.7% | -25.9% | -52.5% | -8.7% | -19.3% | -14.9% |
| — | -390.2% | -157.9% | -193.5% | -139.8% | +247.8% | -158.4% | -55.1% | -3607.1% | +71.9% | +181.5% | +37.0% | +101.0% | +75.0% | -10.5% | +85.8% | -74.1% | -138.9% | -11.5% | -276.5% | -15.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.21 | 0.65 | 1.62 | 1.17 | 1.21 | 0.65 | 0.56 | 0.61 | 0.59 | 0.73 | 0.56 | 0.50 | 0.77 | 0.61 | 0.54 | 0.47 | 0.41 | 0.35 | 0.26 | 0.22 | 0.23 |
| — | +1.1% | +191.6% | +92.4% | +104.2% | -11.7% | +0.3% | +20.7% | -23.4% | +19.2% | +2.8% | +6.4% | +88.3% | +76.4% | +106.9% | +111.5% | +82.3% | +85.5% | +2665.3% | +965.9% | +965.8% | |
| Debt / EBITDA | — | — | — | — | — | 6.03 | — | 36.59 | — | — | 3.70 | 16.64 | 13.32 | — | — | 51.91 | — | — | — | — | — |
| — | — | — | — | — | — | — | +119.9% | — | — | — | -67.9% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.26 | 1.12 | 1.16 | 1.23 | 1.26 | 1.03 | 0.98 | 0.99 | 0.99 | 0.85 | 1.11 | 1.08 | 1.06 | 0.92 | 1.05 | 1.02 | 0.93 | 0.97 | 0.87 | 0.91 | 0.96 |
| — | +9.5% | +18.1% | +23.9% | +26.2% | +20.7% | -11.5% | -8.1% | -5.8% | -7.5% | +5.7% | +6.1% | +13.5% | -5.3% | +20.8% | +11.9% | -3.3% | -18.8% | -75.7% | -70.1% | -63.3% | |
| Quick Ratio | 1.07 | 1.00 | 1.03 | 1.08 | 1.07 | 0.87 | 0.81 | 0.80 | 0.80 | 0.69 | 0.91 | 0.88 | 0.88 | 0.76 | 0.86 | 0.84 | 0.76 | 0.80 | 0.71 | 0.74 | 0.81 |
| — | +14.9% | +27.0% | +34.5% | +34.4% | +25.5% | -10.8% | -9.1% | -9.3% | -8.8% | +5.9% | +4.7% | +15.7% | -4.8% | +21.7% | +13.3% | -6.2% | -20.1% | -78.8% | -70.4% | -64.3% | |
| Interest Coverage | -2.71 | -9.32 | -17.90 | 4.81 | -25.63 | 5.24 | 1.35 | 2.51 | -1.65 | -0.41 | 2.11 | -4.82 | — | — | -1.68 | -1.22 | -0.45 | -0.11 | -21.15 | -0.21 | -1.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AYTU stock.
Aytu BioPharma, Inc.'s current P/E is -1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aytu BioPharma, Inc.'s current operating margin is -11.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aytu BioPharma, Inc.'s business trajectory between earnings reports.